FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
Severe eosinophilic asthma (SEA) is a therapy-resistant respiratory condition with poor clinical control. Treatment efficacy and patient compliance of current therapies remain unsatisfactory. Here, inspired by the remarkable success of chimeric antigen receptor-based cellular adoptive immunotherapies demonstrated...
International Journal of Molecular SciencesReviewTreatment Challenges in Severe Eosinophilic Asthma:Differential Response to Anti-IL-5 and Anti-IL-5R TherapyAgamemnon Bakakos, Nikoleta Rovina and Petros Bakakos *??? ???Citation: Bakakos, A.; Rovina, N.;Bakakos, P. Treatment Challenges inSevere E...
Eosinophilic esophagitis: from pathophysiology to treatment. World J Gastrointest Pathophysiol. 2015;6(4):150–8. Article PubMed PubMed Central Google Scholar Underwood B, Troutman TD, Schwartz JT. Breaking down the complex pathophysiology of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2023...
The FDA has approved benralizumab (Fasenra – AstraZeneca), a humanized monoclonal antibody selective for the interleukin-5 (IL-5) receptor, for add-on maintenance treatment of severe asthma in patients ≥12 years old with an eosinophilic phenotype. Benralizumab is the third anti-IL-5...
These anti-IL-5 drugs have not yet been used clinically for asthma treatment in China. Consequently, this study aims to elucidate the overall safety profile of anti-IL-5 treatments, highlight similarities and differ- ences in their safety profiles, and identify potential novel safety signals to...
In the near future, the results of large trials using 'omics' technologies will certainly identify new, more 'upstream' biomarkers of eosinophilic inflammation, that will ultimately lead to the ideal targeted treatment for patients with eosinophilic asthma. Expert commentary: Of currently used ...
Understanding the molecular mechanisms and heterogeneity of asthma has allowed the discovery of two distinct endotypes based on the mechanisms driving the
Patients with EGPA also require management of asthma. Treatment is the same as for asthma in the general population, with a stepwise approach tailored to asthma severity. [8] Next: Medical Care What to Read Next on Medscape Related Conditions and Diseases Vasculitis and Thrombophlebitis Hy...
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Mepolizumab (anti-IL 5) and exacerbations of refractory eosinophilic asthma...